(Total Views: 722)
Posted On: 08/25/2021 8:56:41 AM
Post# of 153903
Quote:
leronlimab was associated with a 400%-660% increase in mPFS (modified Progression Free Survival)/12-month PFS (Progression Free Survival) and a 570%-980% increase in mOS (modified Overall Survival) /12-month OS (Overall Survival)
As a comparison Trodelvy (sacituzumab govitecan) had a 57% PFS and a 49% OS.
(15)
(0)
